Decernotinib Market In Global
Decernotinib is a novel, potent, selective and orally available JAK3 inhibitor for the treatment ... Read More
Filgotinib is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.
This report contains market size and forecasts of Filgotinib in global, including the following market information:
Global Filgotinib Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Filgotinib Market Sales, 2017-2022, 2023-2028, (Kg)
Global top five Filgotinib companies in 2021 (%)
The global Filgotinib market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Min Purity Less Than 98% Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Filgotinib include Cayman Chemical, BioVision, Adooq Bioscience, Taiclone, Clearsynth, Biorbyt, APExBIO Technology, Selleck Chemicals and AbMole, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Filgotinib manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Filgotinib Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Filgotinib Market Segment Percentages, by Type, 2021 (%)
Min Purity Less Than 98%
Min Purity 98%-99%
Min Purity More Than 99%
Global Filgotinib Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Filgotinib Market Segment Percentages, by Application, 2021 (%)
Research
Medical
Global Filgotinib Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Filgotinib Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Filgotinib revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Filgotinib revenues share in global market, 2021 (%)
Key companies Filgotinib sales in global market, 2017-2022 (Estimated), (Kg)
Key companies Filgotinib sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Cayman Chemical
BioVision
Adooq Bioscience
Taiclone
Clearsynth
Biorbyt
APExBIO Technology
Selleck Chemicals
AbMole
BOC Sciences
TargetMol
Toronto Research Chemicals
J&K Scientific
Decernotinib is a novel, potent, selective and orally available JAK3 inhibitor for the treatment ... Read More
Fedratinib is a selective inhibitor of JAK2.Fedratinib has potential antineoplastic activity. Fed ... Read More
Lestaurtinib inhibits JAK2, FLT3, and TrkA with IC50s of 0.9, 3, and less than 25 nM, respectivel ... Read More
Gandotinib is identified as being highly selective for JAK2-V617F and has advanced into human cli ... Read More